Catabasis Pharmaceuticals Presents Data Supporting Edasalonexent as a Potential Foundational Treatment for Duchenne Muscular Dystrophy

Stock Information for Catabasis Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.